Drugs / ALN-HTT02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06585449 | Oct 2024 → Jul 2028 expected | Huntington disease | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-HTT02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06585449 ↗ |
| Route | Intrathecal | “ALN-HTT02 will be administered intrathecally” NCT06585449 ↗ |